Author name: ipessentiacom

A secondary medical-use patent can remain a material barrier to generic entry after the compound patent has expired. The challenge

When an official Search Report cites art that a pre-filing search never found, the usual response is to move straight

A case note on the Federal Circuit’s September 3, 2026 nonprecedential decision affirming a claim construction that resulted in judgment

A case note on the Federal Circuit’s August 31, 2026 decision affirming the validity of Exelixis’s crystalline cabozantinib (L)-malate claims

A case note on the District of Delaware’s August 24, 2026 memorandum opinion holding that Lupin’s ~74% ivacaftor generic does

A case note on the D.C. Circuit’s August 25, 2026 decision affirming in part and reversing in part the FDA’s

Patent due diligence is often reduced to a simple question: what patents does the company have? That’s rarely enough. For

Spinal Muscular Atrophy (SMA) is a rare genetic disorder that causes progressive muscle weakness and wasting, impacting voluntary muscle movement.

Sanofi’s recent infringement lawsuits at the Unified Patent Court (UPC) mark a pivotal moment for pharmaceutical patent litigation. Background: Sanofi’s

Update: Teva Granted 30-Day Stay on Inhaler Patents’ Orange Book Delisting Last week, a federal judge in New Jersey granted